Nifedipine Ennogen Ip

Nifedipine, the active ingredient in Nifedipine Ennogen Ip, is a calcium channel blocker presented as an oral dosage form for oral use. It lowers blood pressure, relieves chest pain from angina, and improves blood flow in Raynaud's phenomenon, primarily in adult patients requiring vascular smooth‑muscle relaxation.

GNH USA supplies Nifedipine Ennogen Ip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution worldwide.

Nifedipine is a calcium channel blocker used to manage vascular and cardiac conditions.

Hypertension: reduces systemic vascular resistance to lower blood pressure. Angina pectoris: improves coronary blood flow to relieve chest pain. Raynaud's phenomenon: enhances peripheral circulation to decrease vasospastic attacks.

Nifedipine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache due to vasodilation. - Flushing: warmth and redness of skin, especially on face and neck. - Peripheral edema: swelling of ankles or feet. - Dizziness: light‑headed sensation, particularly upon standing. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack, especially in patients with pre‑existing coronary disease. - Atrioventricular block: rare conduction disturbances requiring medical attention. - Liver enzyme elevation: rare hepatic dysfunction. - Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity.

When prescribing Nifedipine, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular assessment: evaluate baseline blood pressure and heart rate before initiation. - Concomitant nitrates: avoid combined use due to risk of profound hypotension. - Elderly patients: start with lower doses and monitor for orthostatic effects. - Liver impairment: adjust dosing in moderate to severe hepatic dysfunction. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nifedipine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Grapefruit juice: inhibits CYP3A4 metabolism, leading to increased nifedipine plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic accumulation. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia, requiring blood pressure monitoring. - Diuretics: additive blood pressure‑lowering effect, monitor for dehydration. - Anticonvulsants (e.g., carbamazepine, phenytoin): may reduce nifedipine concentrations.